Document is current

Any future updates will be listed below

Reducing pharmaceutical reimbursement price risk to lower national health expenditures without lowering R&D incentives

Crossref DOI link: https://doi.org/10.1007/s42495-018-0002-7

Published Online: 2018-12-03

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark